A Randomized, Double-Blind, Placebo-Controlled, 2-Cohort, Phase III Study of Saruparib Combined with Physician's Choice of Androgen Receptor Pathway Inhibitor in Patients with Metastatic Hormone-Sensitive Prostate Cancer, Previously Treated with Docetaxel or PSMA-Directed 177Lutetium-Containing Therapy without Disease Progression, and with Prostate-Specific Antigen Greater Than or Equal to 0.2 ng/mL: EvoPAR-Prostate05

Clinical Trial Information

Trial Phone: 321-841-7246

Principal Investigator: Hatem Hassanein, MD

Phase: III

Age Group: ADULTOLDER_ADULT

ClinicalTrials.gov ID: NCT07711002

Objective

The purpose of this study is to compare how well saruparib plus a standard hormone therapy known as an androgen receptor pathway inhibitor (ARPI) works compared with placebo plus an ARPI in men with metastatic hormone-sensitive prostate cancer that has spread beyond the prostate. The study includes men who were previously treated with docetaxel chemotherapy or a prostate-specific membrane antigen (PSMA)-directed lutetium-177 radioligand therapy, have not experienced disease progression, and have a prostate-specific antigen (PSA) level of 0.2 ng/mL or higher.

Share: